Cuviva shifts up through acquisition of ScientificMed – creates leading vendor in Remote Patient Monitoring and Digital Therapeutics
Through the acquisition of ScientificMed, Cuviva takes an active and leading role in the development of a comprehensive range of values that includes both broad solutions for distance monitoring and follow-up of chronically ill and specialized digital therapies in oncology today, and subsequently more specific diagnostic areas.
Cuviva’s software platform makes it possible to move much of the care home to the patient. The basic care contact can take place via real-time communication and with sensor-based, high-quality data that is transferred between the patient and the healthcare staff. The result is increased accessibility, better medical quality and improved continuity for the individual as well as a better working environment for the healthcare staff. Cuviva is the leading vendor in Sweden in remote communication and remote patient monitoring of multimorbidity and frail elderly, and has today also the broadest platform for healthcare and care at home.
Since 2012, ScientificMed has, together with healthcare providers, patients, pharmaceutical companies and Karolinska Institutet, developed a platform for digital therapeutics for specific drug treatments and health interventions. The platform is used by healthcare professionals and patients to improve treatment outcomes in cancer care and other diagnostic areas.
– Healthcare is facing a number of paradigm shifts: Patients will be cared for more often at home instead of in hospital. The care will go from reactivity to proactivity – where remote patient monitoring earlier will detect a deterioration of the patient’s health and thus healthcare personnel also earlier will be able to take measures, to avoid, for example, unnecessary emergency hospital visits. The treatments will increasingly also be digital – with both digital therapeutics and digital support for the treatment. Cuviva’s vision since the start in 2016 has always been to be a driving force in these paradigm shifts – to create better health for those patients with the greatest need, and to make a strong contribution to increased quality and efficiency in healthcare. Through the acquisition of ScientificMed, Cuviva is broadening its offering to new customer groups and partners, so that we can drive this change in the market in an even better way. ScientificMed has an extremely sharp team, with unique expertise and extensive experience in developing digital therapies and health interventions. We see that this acquisition creates great value for all our customers and also great synergies in product development. ScientificMed also has a very strong customer portfolio with great strategic value for us. We believe that the market will undergo major change in the coming years, and we intend to be active in the coming consolidation, says Henrik Cederqvist, co-founder and CEO of Cuviva.
– It is very gratifying that we are now joining forces with Cuviva. With Cuviva’s broad and well-developed platform, we can now meet the market’s needs in an even better way. We can make a faster investment going forward both in the Nordic region and more widely internationally, says Jan Fjellström, CEO and co-founder of ScientificMed.
In connection with the acquisition, several of ScientificMed’s owners choose to become co-owners of Cuviva, e.g. the Leksell family’s investment company Bonit Capital and Fabian Fischer – co-founder of Adlibris and Apotea.
– We have been following Cuviva for a long time and are impressed by the team and the scalable platform they have built. They have a growth plan that appeals to us and we are convinced that ScientificMed’s value proposition can be developed and scaled up faster together with Cuviva. Bonit has invested for a long time in healthcare and we see that e-health in general, and digital support for healthcare at home in particular, is a very interesting area. We look forward to supporting Cuviva to become a leading player in remote patient monitoring in Sweden and internationally, says Richard Leksell, Partner at Bonit Capital.